- Home
- ICLR
ICLR
ICON plc
as 11-20-2024 4:00pm EST
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
| Founded: | 1990 | Country: | Ireland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 15.7B | IPO Year: | 1998 |
| Target Price: | $290.60 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.99 | EPS Growth: | 44.49 |
| 52 Week Low/High: | $183.38 - $347.72 | Next Earning Date: | 10-23-2024 |
| Revenue: | $8,306,823,000 | Revenue Growth: | 3.63% |
| Revenue Growth (this year): | 4% | Revenue Growth (next year): | 3.16% |
Latest ICON plc News
ICLR Breaking Stock News: Dive into ICLR Ticker-Specific Updates for Smart Investing
Insider Monkey
6 days ago
ICON Public Limited Company (ICLR): Among 12 High Growth Large Cap Stocks to Buy Now
Simply Wall St.
7 days ago
Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Business Wire
8 days ago
ICON plc to Present at the Jefferies London Healthcare Conference
Zacks
24 days ago
ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls
GuruFocus.com
a month ago
ICON's $650 Million Power Play: Can This Bold Move Reverse a 21% Stock Plunge?
Simply Wall St.
a month ago
ICON Third Quarter 2024 Earnings: Misses Expectations
GuruFocus.com
a month ago
Icon PLC (ICLR) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...
Morningstar Research
a month ago
Analyst Report: ICON Public Limited Company
Compare ICLR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ICLR ICON plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.